Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 21, 2007

View Archived Issues

Recent Sumitomo Chemical patents disclose novel therapeutic agents for chronic renal failure

Omega-3 fatty acids may prevent development of psychosis in at-risk adolescents

Biological mechanism of treatment response with gene therapy for Parkinson's disease

Single-agent activity seen with perifosine in malignant gliomas

Pooled data show efficacy of desvenlafaxine in depression across ages, genders

Recent Memory and AstraZeneca patents describe new antidepressive and antipsychotic agents

Novel therapeutic agents for cardiovascular diseases disclosed in recent patents

Anti-CD22 agent plus chemotherapy yields positive preclinical results in pre-B ALL

Dock-and-lock-generated dimeric interferon shows potential in cancer therapy

Epratuzumab/rituximab combination active in recurrent non-Hodgkin's lymphoma

New data presented on lymphoma treatment with rituximab and mitumprotimut-T

Phosphagenics reports positive results from a phase I clinical trial of TPM and oxycodone

Oxford Genome Sciences and Amgen enter collaboration for therapeutic antibodies in cancer

Novelos enters license agreement with Lee's Pharmaceutical for NOV-002 and NOV-205

Clinical Data initiates long-term safety and tolerability study of vilazodone for depression

Cytopia initiates phase II trial of anticancer vascular-disrupting agent CYT-997

Lilly acquires worldwide rights to BioMS Medical's MBP-8298 for multiple sclerosis

Aspreva shareholders approve acquisition by Galenica

Synthetic Blood finalizes Oxycyte phase IIb clinical trial protocol for traumatic brain injury

Commencement of phase II clinical trial of ZymoGenetics' IL-21 in metastatic melanoma

Innocoll initiates dosing in phase II clinical trial of CollaRx gentamicin topical for foot ulcers

GenVec receives NIH funding for gene-based drug therapy to treat severe balance disorders

Schering-Plough reports positive results from study of asenapine for acute schizophrenia

FDA grants orphan drug designation to Insmed's Iplex for myotonic muscular dystrophy

FDA approves new mechanism of action labeling for CV Therapeutics' Ranexa for angina

AMAG Pharmaceuticals submits NDA to FDA for ferumoxytol for chronic kidney disease

FDA issues nonapprovable letter for Indevus' Valstar

GSK submits NDA to FDA for Promacta for idiopathic thrombocytopenic purpura

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...